Here's why we took a position in the iShares NASDAQ Biotechnology Index.
Not only did hedge funds as a class underperform the S&P 500 by fully 10% through May 10, but only a small sliver of funds managed to outperform it.
"I've been all dollar, all the time."
Carter Lecraw discusses his red, white and blue investing philosophy.
Earnings guidance was negative for seventh straight quarter.
Cerner is a standout, says Barry Randall.